Nautilus Biotechnology Inc reports results for the quarter ended in September - Earnings Summary

Nautilus Biotechnology

31/10/2023 13:32

* Nautilus Biotechnology Inc  NAUT.OQ  reported a quarterly
adjusted loss of 13 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 17 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Nautilus Biotechnology Inc's reported EPS for the quarter
was a
loss of 13 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Nautilus Biotechnology Inc shares had fallen by 25.9% this
quarter and gained 30.0% so far this year.
    * The company reported a quarterly loss of $15.88 million.
    * Wall Street's median 12-month price target for Nautilus
Biotechnology Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
October 31 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.17          -0.13          Beat
 Jun. 30 2023      -0.15          -0.13          Beat
 Mar. 31 2023      -0.17          -0.12          Beat
 Dec. 31 2022      -0.15          -0.11          Beat